Drug Approval | May 07, 2026
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Subscribe To Our Newsletter & Stay Updated
